Audentes Therapeutics

General Information

We are a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. We believe that gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the affected gene to cells, resulting in production of the normal protein. We have identified and built a compelling portfolio, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome Type 1, or CN Type 1, AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT, and AT982 for the treatment of Pompe disease. We expect our first two product candidates, AT132 and AT342, to enter clinical development in 2016.

Employees: 75
Founded: 2012
Contact Information
Address 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, US
Phone Number (415) 638-6556
Web Address
View Prospectus: Audentes Therapeutics
Financial Information
Market Cap $315.3mil
Revenues $0.0 mil (last 12 months)
Net Income $-32.9 mil (last 12 months)
IPO Profile
Symbol BOLD
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Cowen and Company/ Piper Jaffray
CO-Managers Wedbush PacGrow
Expected To Trade: 7/20/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change